Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE:GSK) novel treatment, Ojjaara (momelotinib), for adults with intermediate- or high-risk myelofibrosis and anemia. This announcement comes after a three-month delay due to the need for additional data review.
The FDA has approved Ojjaara, a drug developed by GSK plc (LSE:GSK), for the treatment of intermediate or high-risk myelofibrosis in adults with anaemia, the pharmaceutical company announced on Monday. The approval comes following a three-month delay due to an FDA request for additional information.